These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36328326)

  • 1. Health and Economic Evaluation of Vaccination Against Pertussis in China: A 40-Year Analysis.
    Wu D; Jing R; Zheng H; He K; Li Y; Yu W; Yin Z; Fang H
    Value Health; 2023 May; 26(5):666-675. PubMed ID: 36328326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.
    Ekwueme DU; Strebel PM; Hadler SC; Meltzer MI; Allen JW; Livengood JR
    Arch Pediatr Adolesc Med; 2000 Aug; 154(8):797-803. PubMed ID: 10922276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
    Ren J; Huang Z; Tian J; Li Z; Shen S; Yan H; Wang N; Hu J; Ma X; Ma Z; Liu J; Lu Y; Sun X
    Vaccine; 2024 Aug; 42(21):126162. PubMed ID: 39069462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).
    Ding Y; Yeh SH; Mink CA; Zangwill KM; Allred NJ; Hay JW
    Vaccine; 2013 May; 31(22):2558-64. PubMed ID: 23583811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of the routine childhood immunization program in the United States, 2009.
    Zhou F; Shefer A; Wenger J; Messonnier M; Wang LY; Lopez A; Moore M; Murphy TV; Cortese M; Rodewald L
    Pediatrics; 2014 Apr; 133(4):577-85. PubMed ID: 24590750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.
    McGarry LJ; Krishnarajah G; Hill G; Masseria C; Skornicki M; Pruttivarasin N; Arondekar B; Roiz J; Pelton SI; Weinstein MC
    PLoS One; 2014; 9(1):e72723. PubMed ID: 24416118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
    Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
    Hoshi SL; Seposo X; Okubo I; Kondo M
    Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
    Iskedjian M; Walker JH; De Serres G; Einarson TR
    Paediatr Drugs; 2005; 7(2):123-36. PubMed ID: 15871632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.
    Cho BH; Acosta AM; Leidner AJ; Faulkner AE; Zhou F
    Prev Med; 2020 May; 134():106066. PubMed ID: 32199910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health impact and return on investment of Belgium's pediatric immunization program.
    Carrico J; Mellott CE; Talbird SE; Bento-Abreu A; Merckx B; Vandenhaute J; Benchabane D; Dauby N; Ethgen O; Lepage P; Luyten J; Raes M; Simoens S; Van Ranst M; Eiden A; Nyaku MK; Bencina G
    Front Public Health; 2023; 11():1032385. PubMed ID: 37427250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Tanaka M; Okubo R; Hoshi SL; Kondo M
    Vaccine; 2024 Mar; 42(8):2081-2088. PubMed ID: 38418340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
    Decker MD; Greenberg DP; Johnson DR; Pool V
    Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.